ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
Degarelix (Firmagon) (Ferring Pharmaceuticals) is a new gonadotropin-releasing hormone (GnRH) antagonist permitted and approved for use in the treatment of hormone-dependent prostate cancer. It is recommended to administer the drug subcutaneously in the abdomen in a starting dose of 240 mg, followed...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/107 |